Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anagrelide in Treatment-naïve High-risk Essential Thrombocythemia
NCT03232177Phase 4Completed
- Sponsor
- Yuhan
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anagrelide in essential thrombocythemia (ET), sponsored by Yuhan. Started Jun 2017; status: completed.
02
Drugs
anagrelide
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT03232177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232177.